secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001683168-23-007924
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma Q3 2023 revenues surge to $5.96M on Nora Pharma acquisition; net loss narrows to $0.04/sh
--------------------------------------------------------------------------------

- Gross revenues $5,957,668 for Q3 2023, up from $132,808 a year earlier, driven by Nora Pharma Inc. acquisition.
- Net loss from operations narrowed to $651,482 ($0.04 per share) from $1,457,019 ($0.12 per share) in Q3 2022.
- Sequential revenue growth: 7.1% from Q2 2023 ($5,560,865) and 21.7% from Q1 2023 ($4,894,053).
- CEO Steve Slilaty stated focus on cost cutting and reaching profitability as key goals going forward.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316823007924/0001683168-23-007924-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316823007924/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-007924

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer